Joe DePinto

1 week ago | ajmc.com | Laura Joszt |Joe DePinto

Innovative financing and reimbursement models, such as annuity payments and value-based outcomes, hold significant promise in overcoming cost-related barriers to cell and gene therapy (CGT) adoption, said Joe DePinto, head of cell, gene, and advanced therapies, McKesson. In addition, policy makers are also exploring initiatives to improve patient access to these high-cost treatments. Transcript was lightly edited; captions were auto-generated.

2 weeks ago | pharmacytimes.com | Kennedy Ferruggia |Joe DePinto

CommentaryVideoApril 29, 2025Author(s):,Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies. In an interview with Pharmacy Times®, Joe DePinto, head of cell, gene, and advanced therapies at McKesson, discussed the early stages of cell and gene therapy (CGT), sharing that it is facing multiple challenges in commercial adoption despite recent FDA approvals.